Fx-5A peptide complex

Phase 1Biologic

NNational Heart, Lung, and Blood Institute (NHLBI)

Fx-5A peptide complex is one of 42 biologic programs targeting Cardiovascular Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseRecruiting

Cardiovascular DiseasePhase 1

Recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Byetta

Retatrutide

1 3

Zilebesiran

Alnylam Pharmaceuticals

Repatha

5 5

Praluent

Regeneron

Preclinical

1 6

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 7

Benicar

Novartis

Preclinical

1 8

Farxiga

AstraZeneca

Preclinical

1 9

Mounjaro

Eli Lilly

Preclinical

1 10

Myrbetriq

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiovascular Disease1 trial

An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT04216342·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fx-5A peptide complex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fx-5A peptide complex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fx-5A peptide complex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Fx-5A peptide complex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News